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Background
The current standard of preventive care for poorly con-
trolled seasonal AR symptoms is subcutaneous immu-
notherapy (SCIT) with allergen extracts, administered in
a physician’s office. As an alternative to SC administra-
tion, sublingual immunotherapy (SLIT) is now an option
for patients. Oralair™ and Grazax™ are two SLIT
agents currently available in many countries. However,
head to head comparative data between the three
options are not available. In this study, an indirect com-
parison on efficacy, safety and cost was undertaken
between Oralair™, Grazax™ and SCIT.
Methods
A systematic review of major databases was conducted
from January 1980 to December 2012 for double blind pla-
cebo controlled randomized trials evaluating Oralair™,
Grazax™ or SCIT in patients with grass-induced seasonal
AR. Using placebo as the common control, an indirect sta-
tistical comparison between treatments was performed
using meta regression analysis with active drug as the pri-
mary independent variable. Other variables considered in
the regression model included year of study publication,
geographic region where the trial was conducted, trial
duration, duration of immunotherapy, number of asth-
matic patients enrolled in the trial, number of allergens
and patient type (adults vs. children). A cost comparison,
which included costs for drug therapy, pharmacy fees,
physician visits and indirect costs (i.e. patient travel and
lost productivity) was also undertaken.
Results
Overall, 20 placebo-controlled trials met the inclusion cri-
teria for indirect analysis. Keeping in mind the caveats
associated with comparisons across clinical trials, the
indirect analysis suggested a possibility for improved effi-
cacy with Oralair™ over SCIT (standardized mean differ-
ence [SMD] in AR symptom control = - 0.21; p = 0.007)
and Grazax™ (SMD = - 0.18; p = 0.018). In addition, the
meta regression analysis did not identify significant differ-
ences in the risk of discontinuation due adverse events
between the three therapies. Oralair™ was also associated
with cost savings against year round SCIT ($2,471), seaso-
nal SCIT ($948) and Grazax™ ($1,168) during the first
year of therapy.
Conclusions
Through an indirect comparison of placebo controlled
trials, the evaluation suggested that Oralair™ has at least
non-inferior efficacy and comparable safety against SCIT
and Grazax™ at a lower annual cost.
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